The U.S. Food and Drug Administration (FDA) approved lefamulin on August 19, 2019, making it the first pleuromutilin antibiotic available for systemic administration in humans.

6.17-6.23 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

The FDA first approved upadacitinib on August 16, 2019, for the treatment of moderate to severe rheumatoid arthritis in adults who have not responded well to methotrexate or other similar medications.

What is the structure of YL202/BNT326, and why is it exhibiting such high toxicity?

The U.S. Food and Drug Administration (FDA) granted approval for Fedratinib on August 16, 2019.

Jun 21st latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

KalVista Submits New Drug Application to FDA for Sebetralstat, the First Oral On-demand Treatment for Hereditary Angioedema.

The U.S. Food and Drug Administration (FDA) granted approval for Pretomanid on August 14, 2019.

Update on the CAPItello-290 Phase III study of Truqap combined with chemotherapy for advanced or metastatic triple-negative breast cancer.

The U.S. Food and Drug Administration (FDA) approved Pexidartinib on August 2, 2019.

NMD Pharma Gets FDA IND Approval to Start Phase 2 Study of NMD670 in US for Charcot-Marie-Tooth Disease.

The U.S. Food and Drug Administration (FDA) approved Darolutamide, marketed under the brand name Nubeqa, on July 30, 2019.